KTC-1

KTC-1/KTC-1细胞系/KTC-1细胞株/KTC-1人甲状腺癌细胞

Cell line name KTC-1

Synonyms KTC1; KTC1naive

Accession CVCL_6300

Resource Identification Initiative To cite this cell line use: KTC-1 (RRID:CVCL_6300)

Comments Population: Japanese.

Doubling time: ~48 hours (PubMed=10946899).

Omics: Array-based CGH.

Omics: Transcriptome analysis by microarray.

Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.

Sequence variations

Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=29156680).

Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23833040; PubMed=29156680; PubMed=30737244).

Mutation; HGNC; 9801; RAC1; Simple; p.Asp63Val (c.188A>T); Zygosity=Heterozygous (PubMed=30737244).

Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244).

Disease Poorly differentiated thyroid gland carcinoma (NCIt: C6040)

Thyroid carcinoma (ORDO: Orphanet_100088)

Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)

Hierarchy Children:

CVCL_A2CS (KTC1res.1) CVCL_A2CT (KTC1res.2)

Sex of cell Male

Age at sampling 68Y

Category Cancer cell line

STR profile Source(s): PubMed=18713817; PubMed=30737244

 

Markers:

Amelogenin X,Y

CSF1PO 10,12

D3S1358 14,15

D5S818 11,12

D7S820 11

D8S1179 11,14

D13S317 11

D16S539 12

D18S51 12,13

D21S11 29

FGA 23,26

TH01 9

TPOX 11

vWA 14,17

 

Run an STR similarity search on this cell line

Publications

PubMed=10946899; DOI=10.1210/jcem.85.8.6732

Kurebayashi J., Tanaka K., Otsuki T., Moriya T., Kunisue H., Uno M., Sonoo H.

All-trans-retinoic acid modulates expression levels of thyroglobulin and cytokines in a new human poorly differentiated papillary thyroid carcinoma cell line, KTC-1.

J. Clin. Endocrinol. Metab. 85:2889-2896(2000)

 

CLPUB00144

Kurebayashi J., Tanaka K., Yamamoto Y., Okubo S., Sonoo H.

Human epidermal growth factor receptor 1 and thrombospondin-1 in thyroid cancer.

(In book chapter) Trends in thyroid cancer research. Horizons in cancer research, Vol. 37; Milton C.A. (eds.); pp.89-116; Nova Science Publishers; Hauppauge; USA (2007)

 

PubMed=18713817; DOI=10.1210/jc.2008-1102; PMCID=PMC2582569

Schweppe R.E., Klopper J.P., Korch C.T., Pugazhenthi U., Benezra M., Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A. 3rd, Smallridge R.C., Haugen B.R.

Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.

J. Clin. Endocrinol. Metab. 93:4331-4341(2008)

 

PubMed=23833040; DOI=10.1210/jc.2013-2383; PMCID=PMC3763971

Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M., Ibrahimpasic T., Ghossein R.A., Fagin J.A.

Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.

J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013)

 

PubMed=25675381; DOI=10.1210/jc.2014-2764; PMCID=PMC4422887

von Roemeling C.A., Marlow L.A., Pinkerton A.B., Crist A., Miller J., Tun H.W., Smallridge R.C., Copland J.A. 3rd

Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals stearoyl CoA desaturase 1 as a novel therapeutic target.

J. Clin. Endocrinol. Metab. 100:E697-E709(2015)

 

PubMed=29156680; DOI=10.18632/oncotarget.21262; PMCID=PMC5689570

Antonello Z.A., Hsu N., Bhasin M., Roti G., Joshi M., Van Hummelen P., Ye E., Lo A.S., Karumanchi S.A., Bryke C.R., Nucera C.

Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAF(V600E).

Oncotarget 8:84743-84760(2017)

 

PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953; PMCID=PMC6522280

Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C., Copland J.A. 3rd, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N., Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R., Fagin J.A., Schweppe R.E.

Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies.

Clin. Cancer Res. 25:3141-3151(2019)